Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M97,966Revenue $M16,383Net Margin (%)10.9Altman Z-Score6.0
Enterprise Value $M100,028EPS $1.1Operating Margin %17.0Piotroski F-Score7
P/E(ttm)55.1Beneish M-Score-2.1Pre-tax Margin (%)14.9Higher ROA y-yN
Price/Book6.510-y EBITDA Growth Rate %-1.4Quick Ratio1.6Cash flow > EarningsY
Price/Sales6.05-y EBITDA Growth Rate %-14.3Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow62.5y-y EBITDA Growth Rate %-22.0ROA % (ttm)5.4Higher Current Ratio y-yN
Dividend Yield %2.5PEG--ROE % (ttm)11.8Less Shares Outstanding y-yY
Payout Ratio %138Shares Outstanding M1,668ROIC % (ttm)5.1Gross Margin Increase y-yY

Gurus Latest Trades with BMY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYVanguard Health Care Fund 2015-06-30 Add0.11%$63 - $69.15
($65.88)
$ 58.75-11%Add 1.90%43,718,751
BMYMario Gabelli 2015-06-30 Reduce-0.01%$63 - $69.15
($65.88)
$ 58.75-11%Reduce 3.66%678,636
BMYRonald Muhlenkamp 2015-06-30 Reduce-0.01%$63 - $69.15
($65.88)
$ 58.75-11%Reduce 0.26%211,620
BMYDodge & Cox 2015-06-30 Reduce$63 - $69.15
($65.88)
$ 58.75-11%Reduce 7.86%80,928
BMYKen Fisher 2015-06-30 Add$63 - $69.15
($65.88)
$ 58.75-11%Add 6.77%34,636
BMYKahn Brothers 2015-06-30 Add$63 - $69.15
($65.88)
$ 58.75-11%Add 1.41%28,800
BMYFirst Eagle Investment 2015-06-30 Reduce$63 - $69.15
($65.88)
$ 58.75-11%Reduce 8.05%13,325
BMYVanguard Health Care Fund 2015-03-31 Add0.53%$58.48 - $68.47
($62.6)
$ 58.75-6%Add 9.85%42,902,031
BMYBrian Rogers 2015-03-31 Reduce-0.09%$58.48 - $68.47
($62.6)
$ 58.75-6%Reduce 7.18%5,814,800
BMYMario Gabelli 2015-03-31 Reduce$58.48 - $68.47
($62.6)
$ 58.75-6%Reduce 0.75%704,425
BMYKen Fisher 2015-03-31 Add$58.48 - $68.47
($62.6)
$ 58.75-6%Add 5.54%32,441
BMYRonald Muhlenkamp 2015-03-31 Reduce$58.48 - $68.47
($62.6)
$ 58.75-6%Reduce 0.06%212,170
BMYDodge & Cox 2015-03-31 Reduce$58.48 - $68.47
($62.6)
$ 58.75-6%Reduce 3.52%87,828
BMYVanguard Health Care Fund 2014-12-31 Add0.08%$48.92 - $61.3
($56.49)
$ 58.754%Add 1.50%39,056,361
BMYKahn Brothers 2014-12-31 Add0.01%$48.92 - $61.3
($56.49)
$ 58.754%Add 2.71%28,400
BMYKen Fisher 2014-12-31 Reduce$48.92 - $61.3
($56.42)
$ 58.754%Reduce 39.96%30,739
BMYRonald Muhlenkamp 2014-12-31 Reduce$48.92 - $61.3
($56.49)
$ 58.754%Reduce 0.09%212,290
BMYRuane Cunniff 2014-12-31 Buy $48.92 - $61.3
($56.53)
$ 58.754%New holding3,670
BMYDodge & Cox 2014-12-31 Add$48.92 - $61.3
($56.49)
$ 58.754%Add 0.66%91,028
BMYMario Gabelli 2014-12-31 Add$48.92 - $61.3
($56.49)
$ 58.754%Add 1.35%709,715
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDREOTTI LAMBERTODirector 2015-08-03Sell315,000$65.36-10.11view
Caldarella Joseph CSVP & Controller 2015-06-04Sell16,972$65.71-10.59view
Schmukler Louis SPres., Global Mfg. & Supply 2015-03-16Sell12,000$66.96-12.26view
Cuss Francis MEVP & CSO 2015-03-16Sell114,666$67.81-13.36view
Moed Samuel JSVP, Strat Plan & Analysis 2015-03-13Sell591$66.67-11.88view
Moed Samuel JSVP, Strat Plan & Analysis 2015-03-10Sell10,343$65.84-10.77view
Elicker John ESVP Pub Affairs & Inv Relation 2015-03-06Sell10,468$66.24-11.31view
LEUNG SANDRAGeneral Counsel & Secretary 2015-02-17Sell11,746$60.39-2.72view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-12Sell3,880$59.26-0.86view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-06Sell21,478$60.15-2.33view

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
Weekly Insider Sells Highlight: IMS, NOW, BMY, EA Aug 11 2015 
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
gild Jun 02 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 

More From Other Websites
Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up Sep 03 2015
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo... Sep 02 2015
Bristol-Myers/AbbVie Cancer Drug Gets Priority Review Sep 02 2015
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer... Sep 02 2015
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer... Sep 02 2015
Bristol-Myers Squibb to Present New Data from its Immuno-Oncology Clinical Development Programs at... Sep 02 2015
Bristol-Myers Squibb (BMY) Stock Climbs on FDA Acceptance for Expanded Opdivo Drug Use Sep 02 2015
8:03 am Bristol-Myers announces that the FDA has accepted for filing and review the sBLA for Opdivo;... Sep 02 2015
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo... Sep 02 2015
Will Bristol-Myers (BMY) Stock Be Helped by Myeloma Gaining FDA Priority Review Approval? Sep 01 2015
Bristol-Myers to Pay up to $1.25B for Right to Buy Promedior Sep 01 2015
3 ways Tampa Bay can capitalize on the Johnson & Johnson deal Sep 01 2015
[$$] Bristol-Myers Myeloma Drug Accepted for FDA Review Sep 01 2015
U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for... Sep 01 2015
U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for... Sep 01 2015
Financial Briefs Aug 31 2015
Bristol-Myers Inks Another Immuno-Oncology Drug Deal Aug 31 2015
Bristol-Myers buys rights to fibrosis drug Aug 31 2015
Bristol-Myers buys rights to fibrosis drug Aug 31 2015
Bristol-Myers Granted Right to Buy Promedior Aug 31 2015
Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its... Aug 31 2015
Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its... Aug 31 2015
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration... Aug 30 2015
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration... Aug 30 2015
Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside Aug 28 2015
Bristol-Myers Squibb's success in Tampa was a major draw for Johnson & Johnson Aug 27 2015
Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University Aug 27 2015
2Q15 Performance of AstraZeneca’s ING Segment Aug 26 2015
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015 Aug 24 2015
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015 Aug 24 2015
U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application... Aug 17 2015
FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line... Aug 13 2015
BUZZ-Western pharma losing ground to local firms in China Aug 13 2015
U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application... Aug 12 2015
uniQure Announces Receipt of $53 Million from Bristol-Myers Squibb for Target Selection Payment and... Aug 10 2015
Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM)... Aug 03 2015
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
Gilead beats Street 2Q forecasts on surge in sales, profit Jul 28 2015
Drugmaker Pfizer tops Street 2Q forecasts, raises forecast Jul 28 2015
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo... Jul 28 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization... Jul 27 2015
Bristol-Myers wins approval for 1st hepatitis C type 3 drug Jul 24 2015
Surging new drug sales highlight strong Bristol-Myers Q2 Jul 23 2015
Bristol-Myers reports 2Q loss Jul 23 2015
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo... Jul 23 2015
European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe... Jul 22 2015
CheckMate-025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial... Jul 22 2015
Bristol-Myers says HIV drug gets FDA incentives Jul 21 2015
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1... Jul 21 2015
Bristol-Myers Squibb to shift research jobs Jun 25 2015
Tests for new cancer drugs not reliable enough, doctors say Jun 02 2015
New CEO takes over evolving drugmaker Bristol-Myers Squibb May 05 2015
MEDIA-Global annual spending on cancer drugs surges to $100 bln - FT May 04 2015
Final Glance: Pharmaceuticals companies Apr 29 2015
Midday Glance: Pharmaceuticals companies Apr 29 2015
Early Glance: Pharmaceuticals companies Apr 29 2015
New meds help drugmakers weather strong dollar, other issues Apr 28 2015
Pfizer, despite dollar and generics fight, still impresses Apr 28 2015
Merck hurdles Wall Street forecasts Apr 28 2015
Bristol-Myers beats Street 1Q forecasts Apr 28 2015
EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
Bristol-Myers: 2 cancer drugs beat 1 against melanoma Apr 20 2015
Studies: Merck drug Keytruda effective against 3 cancers Apr 19 2015
Specialty, generic drug costs drive Medicaid costs up Apr 11 2015
Bristol-Myers to invest in Dutch gene therapy company uniQure Apr 06 2015
Roche open to alliances in hunt for cancer drug combinations Apr 01 2015
Europe pushes back verdict on Bristol immune system cancer drug Mar 27 2015
BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Digital Ally, Home Loan Servicing Feb 23 2015
BUZZ-U.S. STOCKS ON THE MOVE-Rigel, oil stocks, Boeing Feb 23 2015
Merck, Bristol heat up immunotherapy race in lung cancer Jan 12 2015
Bristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath,... Nov 14 2014
Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha... Oct 28 2014
BUZZ-Innate Pharma: Citi lauds French biotech firm's cancer work Oct 09 2014
AstraZeneca heart drug gets preferred status in U.S. Oct 06 2014
Bristol immune drug shows strong effect in melanoma study Sep 29 2014
Bristol immune drug shows strong effect in melanoma study Sep 29 2014
Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Sep 26 2014
French cancer immunotherapy specialist OSE Pharma prepares IPO Sep 18 2014
Bristol-Myers profit tops forecasts, helped by newer drugs Jul 24 2014
AstraZeneca takes control of diabetes venture for $4.1bn Dec 19 2013

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK